The objectives of the Genetically Engineered Mouse (GEM) shared resource is to aid Cancer Center investigators with the design and execution of experiments to utilize animal models for the investigation of the progression of cancer and in the preclinical evaluation of therapies for the treatment of cancer. Although the use of animal models provides an invaluable source of reagents for preclinical testing and the investigation of regulatory mechanisms in vivo, in a physiologically regulated system, the use of animals is costly with respect to equipment, animal resources and technical expertise. GEM will serve as a resource for the execution and training in the use of all animal manipulations needed in the Cancer Center. The GEM shared resource will minimize the cost of utilizing animal models in the Cancer Center by consolidating animal expertise and associated equipment. This will ensure an efficient use of animal research at minimal cost. The GEM shared resource will serve Cancer Center investigatory by aiding in the following tasks. 1. Generate transgenic mice by the micro injection of DNA into the one celled mouse embryo. 2. Generate mutant mice by the manipulation of mouse Embryonic Stem Cells. 3. Preserve lines of mice by cryopreservation. 4 Assist investigators with the importation and exporting of lines of mice. The accomplishments of these tasks will allow the GEM Shared Resource to serve as a repository for all genetically engineered mouse models and techniques for Cancer Center investigators and will ensure efficient use of animal resources by Cancer Center investigators.

Public Health Relevance

The GEM Shared Resource will provide Cancer Center Investigators with the ability to investigate both the causes of cancer in vivo. This will aide in the development of improved cancer therapies for treatments and diagnostics.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
United States
Zip Code
Woodard, Lauren E; Cheng, Jizhong; Welch, Richard C et al. (2017) Kidney-specific transposon-mediated gene transfer in vivo. Sci Rep 7:44904
Saxena, Kapil; Simon, Lukas M; Zeng, Xi-Lei et al. (2017) A paradox of transcriptional and functional innate interferon responses of human intestinal enteroids to enteric virus infection. Proc Natl Acad Sci U S A 114:E570-E579
Heczey, Andras; Louis, Chrystal U; Savoldo, Barbara et al. (2017) CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther 25:2214-2224
Rohira, Aarti D; Yan, Fei; Wang, Lei et al. (2017) Targeting SRC Coactivators Blocks the Tumor-Initiating Capacity of Cancer Stem-like Cells. Cancer Res 77:4293-4304
Ware, Matthew J; Nguyen, Lam P; Law, Justin J et al. (2017) A new mild hyperthermia device to treat vascular involvement in cancer surgery. Sci Rep 7:11299
Gibbons, Don L; Creighton, Chad J (2017) Pan-cancer survey of epithelial-mesenchymal transition markers across the Cancer Genome Atlas. Dev Dyn :
Ha, Kyungsoo; Ma, Chengxian; Lin, Han et al. (2017) The anaphase promoting complex impacts repair choice by protecting ubiquitin signalling at DNA damage sites. Nat Commun 8:15751
Schmueck-Henneresse, Michael; Omer, Bilal; Shum, Thomas et al. (2017) Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells. J Immunol 199:348-362
Wang, Yongquan; Wang, Jianghua; Zhang, Li et al. (2017) RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression. Cancer Res 77:4247-4257
Sreekumar, Amulya; Toneff, Michael J; Toh, Eajer et al. (2017) WNT-Mediated Regulation of FOXO1 Constitutes a Critical Axis Maintaining Pubertal Mammary Stem Cell Homeostasis. Dev Cell 43:436-448.e6

Showing the most recent 10 out of 842 publications